AUG 25, 2020 8:00 AM PDT

How LV and AAV Transfection Platforms will Shape the Future of Gene Therapy Manufacturing

Sponsored by: Mirus

Event Date & Time
DATE:  August 25, 2020
TIME:  8:00am PDT, 10:00am CDT, 11:00am EDT
Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show great promise for treatment of diseases from genetic disorders to cancer. Accordingly, there is an unprecedented need for high titer and large-scale viral vector manufacturing processes to support the growing number of researchers developing biotherapeutics for immunotherapy. Mirus Bio offers an innovative transfection formulation, TransIT-VirusGEN®, for high titer manufacture of both recombinant LV and AAV in adherent or suspension 293-derived cell types. In addition, our prototype LV and AAV enhancers increase functional virus titers 2-3 fold over previously optimized high titer conditions and up to 10-fold over PEI-based formulations. Our data demonstrates that the TransIT-VirusGEN® LV and AAV Kits push the limits of high titer virus production to increase manufacturing capabilities for gene and cell therapy development.
Learning Objectives:
  • Introduce TransIT-VirusGEN® LV and AAV Kits for development and manufacture of Cell and Gene Therapies
  • Understand the need for increasing manufacturing efficiency to generate sufficient doses for large patient populations
  • Highlight the TransIT-VirusGEN® SELECT and upcoming GMP Products and quality control documentation
  • Demonstrate critical parameters for optimized virus production using TransIT-VirusGEN® Reagent and Kits
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

You May Also Like
Loading Comments...